Results 211 to 220 of about 65,591 (261)

Hyper-activation of STAT3 sustains progression of non-papillary basal-type bladder cancer via FOSL1 regulome [PDF]

, 2019
et al,, Vermi, William
core   +1 more source

Integrated transcriptome analysis of CSE1L regarding poor prognosis and immune infiltration in bladder urothelial carcinoma and experimental verification. [PDF]

Front Immunol
Liu R, Ma J, Zhang Y, Zhou Z.
europepmc   +1 more source

Cutaneous Metastasis Following a Six-Year History of Bladder Urothelial Carcinoma in Situ: A Case Report. [PDF]

Cureus
Mammadova J, Patil R, Herman T, Rodriguez VI.   +3 more
europepmc   +1 more source

Prediction of future research trends in bladder urothelial carcinoma: Bibliometric analysis. [PDF]

Medicine (Baltimore)
Shao B, Wu K, Wan S, Sun P, Zuo Y, Xiao L, Fan Z, Pi J, Han Z, Wang J.   +9 more
europepmc   +1 more source

Application of contrast-enhanced ultrasound in diagnosis and grading of bladder urothelial carcinoma. [PDF]

BMC Med Imaging
Zhang HP, Liang RX, Lin XY, Xue ES, Ye Q, Zhu YF.   +5 more
europepmc   +1 more source

Role of anoikis-related gene RAC3 in prognosis, immune microenvironment, and contribution to malignant behavior in vitro and in vivo of bladder urothelial carcinoma. [PDF]

Front Pharmacol
Zhou Y, Huang S, Yang B, Tan J, Zhang Z, Liu W.   +5 more
europepmc   +1 more source

Recurrent bladder urothelial carcinoma complicated with primary bladder large cell neuroendocrine carcinoma: a case report and literature review. [PDF]

Front Oncol
Cui J, Zhao Q, Yu C, Ma P, Li S.
europepmc   +1 more source

Correction to: EMP2 induces cytostasis and apoptosis via the TGFβ/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma. [PDF]

Cell Oncol (Dordr)
Li CF, Chan TC, Pan CT, Vejvisithsakul PP, Lai JC, Chen SY, Hsu YW, Shiao MS, Shiue YL.   +8 more
europepmc   +1 more source

Blockade of the STAT3/BCL-xL Axis Leads to the Cytotoxic and Cisplatin-Sensitizing Effects of Fucoxanthin, a Marine-Derived Carotenoid, on Human Bladder Urothelial Carcinoma Cells. [PDF]

Mar Drugs
Dai WC, Chen TH, Peng TC, He YC, Hsu CY, Chang CC.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Atezolizumab in Urothelial Bladder Carcinoma

Future Oncology, 2017
Metastatic bladder cancer is an aggressive malignancy with a poor prognosis when presenting with advanced stage. Cisplatin-based therapy has been the mainstay of first-line treatment but therapy in second-line setting has been an unmet medical need for decades. Moreover, many patients are unable to receive cisplatin-based therapy.
Zineb, Hamilou, Pernelle, Lavaud, Yohann, Loriot   +2 more
openaire   +2 more sources